Use of an Anti–Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic Dermatitis. Authors: Sabine-Gisela Plötz, M.D., Hans-Uwe Simon, ...

Murine Ba/F3 cells were transfected with cDNA for the α-chain of the murine interleukin-5 (IL-5) receptor and cloned lines of these cells were able to proliferate in response to as little as 2.5 ...

The field of cytokine biology has seen significant advancements, particularly concerning Interleukin-5 (IL-5) and its role in eosinophil-related disorders.

Anti–Interleukin-5 Monoclonal Antibody to Treat Severe Eosinophilic Asthma Author : Parameswaran Nair , M.D., Ph.D. Author Info & Affiliations Published September 25, 2014 ...

Labeling for the interleukin-5 (IL-5) antagonist stipulates use as an add-on maintenance treatment for patients with an eosinophilic phenotype, characterized by a blood eosinophil count of 150 ...

Treatment with Nucala, an interleukin-5 antagonist monoclonal antibody, significantly reduced exacerbations leading to hospitalizations and emergency department visits. The Food and Drug ...

Cite this: Tocilizumab: The First Interleukin-6-Receptor Inhibitor - Medscape - Aug 01, 2008. Abstract and Introduction; IL-6 in RA Pathogenesis; IL-6R Complex; Pharmacology; Pharmacokinetics; ...

Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals.New ...

GSK plc’s interleukin-5 (IL-5) portfolio got boost as depemokimab, an ultra-long-acting biologic targeting IL-5, hit its endpoints in two phase III trials in severe asthma, setting up potential ...

Gluten-stimulated interleukin-2 (IL-2) secretion is useful for diagnosis of celiac disease (CeD), according to a study ...

The FDA is reviewing the BLA for mepolizumab, an interleukin-5 (IL-5) antagonist monoclonal antibody, as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD) with an ...